Patents Assigned to Opexa Therapeutics, Inc.
  • Patent number: 8629108
    Abstract: Described herein is an activated synovial autoreactive T cell and compositions thereof. Methods or preparing T cell compositions that may be used for treating rheumatoid arthritis are also described.
    Type: Grant
    Filed: June 27, 2007
    Date of Patent: January 14, 2014
    Assignee: Opexa Therapeutics, Inc.
    Inventors: Jingwu Zhang Zang, Guangjie Chen, Hong Nie, Ningli Li
  • Publication number: 20120207719
    Abstract: The generation of pancreatic islet-like cells from isolated monocyte-derived stem cells (MDSCs) is provided. MDSCs may be differentiated into pancreatic islet cells by contacting the MDSCs with a differentiation factor or factors. Compositions comprising pancreatic islet cells and methods of using them are also provided.
    Type: Application
    Filed: March 23, 2012
    Publication date: August 16, 2012
    Applicant: Opexa Therapeutics, Inc.
    Inventors: Glenn E. Winnier, Brian S. Newsom, Donna R. Rill, Jim C. Williams
  • Patent number: 7972848
    Abstract: Cross-reactive T cells recognizing both MBP93-105 and HHV-61-13 peptides represent a significant subset of T cells with some degree of TCR degeneracy. It appears that the recognition of the cross-reactive T cells has a less stringent requirement for the flanking residues of the two peptides. In contrast, these flanking residues are critical for the T cell recognition of mono-specific T cells. The association between HHV-6 and autoreactive immune responses to MBP indicates that cross-reactive T cells, peptides from the V-D-J region of the T cell receptor from autoreactive T cells, and antiviral agents may prevent or treat MS.
    Type: Grant
    Filed: August 19, 2009
    Date of Patent: July 5, 2011
    Assignee: Opexa Therapeutics, Inc.
    Inventor: Jingwu Z. Zang